Butylene glycol

The global smart drug delivery systems market reached $12 billion in 2024 and is projected to grow at a CAGR of 17% through 2034, driven by rising chronic disease prevalence and technological advancements.

BD (Becton, Dickinson and Company) has globally launched the world's first cell analyzer combining spectral and real-time cell imaging technologies, enabling researchers to uncover previously invisible cellular insights with greater ease and throughput.

BD (Becton, Dickinson and Company) has treated the first patient in its STANCE clinical trial, evaluating GalaFLEX LITE Scaffold for reducing capsular contracture recurrence during breast implant revision surgery.

Starton Therapeutics successfully used BD's on-body injector to deliver its low-dose lenalidomide formulation, STAR-LLD, offering continuous subcutaneous delivery.

Daye's diagnostic tampon, designed for self-collection of vaginal and cervical fluids, aims to improve STI and HPV screening.